Manufacturer supply top purity Procainamide hydrochloride 614-39-1 with GMP standards
- Molecular Formula: C13H22ClN3O
- Molecular Weight: 271.79
- Appearance/Colour: White to slightly yellow powder
- Melting Point: 165-168 °C
- Refractive Index: 1.6330 (estimate)
- Boiling Point: 421.8 °C at 760 mmHg
- Flash Point: 208.9 °C
- PSA: 58.36000
- Density: 1.2027 (rough estimate)
- LogP: 3.11450
Procainamide hydrochloride(Cas 614-39-1) Usage
|
Definition |
ChEBI: A hydrochloride which has procainamide as the amino component. |
|
General Description |
Procainamide hydrochloride,p-amino-N-[2-(diethylamino)ethyl]benzamidemonohydrochloride, procainamidium chloride (Pronestyl,Procan SR), has emerged as a major antiarrhythmic drug. Itwas developed in the course of research for compoundsstructurally similar to procaine, which had limited effectas an antiarrhythmic agent because of its central nervoussystem (CNS) side effects and short-lived action causedby rapid hydrolysis of its ester linkage by plasma esterases.Because of its amide structure, procainamide hydrochlorideis also more stable in water than is procaine. Aqueoussolutions of procainamide hydrochloride have a pH ofabout 5.5. A kinetic study of the acid-catalyzed hydrolysisof procainamide hydrochloride showed it to be unusuallystable to hydrolysis in the pH range 2 to 7, even at elevatedtemperatures. |
|
Biochem/physiol Actions |
Procainamide hydrochloride is a sodium channel blocker and Class IA anti-arrhythmic. It has also been shown to Inhibit DNA methyltransferase and modulate epigenetic regulation of gene expression. |
|
Veterinary Drugs and Treatments |
Procainamide potentially may be useful for the treatment of ventricular premature complexes (VPC’s), ventricular tachycardia, or supraventricular tachycardia associated with Wolff-Parkinson- White (WPW) syndrome with wide QRS complexes. Higher doses may be beneficial in the treatment of supraventricular tachycardias, although procainamide cannot be considered a first-line agent for this dysrhythmia. |
InChI:InChI=1/C13H21N3O.2ClH/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11;;/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17);2*1H
614-39-1 Relevant articles
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
-
, (2008/06/13)
The present invention provides compositi...
614-39-1 Process route
-
-
614-39-1
procainamide hydrochloride
| Conditions | Yield |
|---|---|
|
|
-
-
614-39-1
procainamide hydrochloride
-
-
75-36-5
acetyl chloride
-
-
32795-44-1
N-acetylprocainamide
| Conditions | Yield |
|---|---|
|
With
pyridine;
at 0 - 20 ℃;
for 18h;
|
20%
|
|
With
potassium hydroxide;
Multistep reaction;
2.) toluene, 60 deg C, 6 h;
|
614-39-1 Downstream products
-
89366-55-2
N3 -[4-(2-Diethylamino-ethylcarbamoyl)-phenyl]-4-octyloxy-isophthalamide
-
89366-61-0
N3 -[4-(2-Diethylamino-ethylcarbamoyl)-phenyl]-4-methoxy-N1 -octyl-isophthalamide
-
89366-56-3
N3 -[4-(2-Diethylamino-ethylcarbamoyl)-phenyl]-N1 -isopropyl-4-octyloxy-isophthalamide
-
89366-63-2
N3 -[4-(2-Diethylamino-ethylcarbamoyl)-phenyl]-N1 -octyl-4-propoxy-isophthalamide